Literature DB >> 24328381

Antiviral potential of cathelicidins.

Peter G Barlow1, Emily Gwyer Findlay, Silke M Currie, Donald J Davidson.   

Abstract

The global burden of morbidity and mortality arising from viral infections is high; however, the development of effective therapeutics has been slow. As our understanding of innate immunity has expanded over recent years, knowledge of natural host defenses against viral infections has started to offer potential for novel therapeutic strategies. An area of current research interest is in understanding the roles played by naturally occurring cationic host defense peptides, such as the cathelicidins, in these innate antiviral host defenses across different species. This research also has the potential to inform the design of novel synthetic antiviral peptide analogs and/or provide rationale for therapies aimed at boosting the natural production of these peptides. In this review, we will discuss our knowledge of the antiviral activities of cathelicidins, an important family of cationic host defense peptides, and consider the implications for novel antiviral therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24328381     DOI: 10.2217/fmb.13.135

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  28 in total

1.  High throughput screening methods for assessing antibiofilm and immunomodulatory activities of synthetic peptides.

Authors:  Evan F Haney; Sarah C Mansour; Ashley L Hilchie; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Peptides       Date:  2015-03-31       Impact factor: 3.750

2.  Cathelicidin LL-37 Induces Semaphorin 3A Expression in Human Epidermal Keratinocytes: Implications for Possible Application to Pruritus.

Authors:  Yoshie Umehara; Yayoi Kamata; Mitsutoshi Tominaga; François Niyonsaba; Hideoki Ogawa; Kenji Takamori
Journal:  J Invest Dermatol       Date:  2015-06-29       Impact factor: 8.551

3.  Carbon Nanoparticles Inhibit the Antimicrobial Activities of the Human Cathelicidin LL-37 through Structural Alteration.

Authors:  Fern Findlay; Jan Pohl; Pavel Svoboda; Priyanka Shakamuri; Kevin McLean; Neil F Inglis; Lorna Proudfoot; Peter G Barlow
Journal:  J Immunol       Date:  2017-08-16       Impact factor: 5.422

4.  LL-37 disrupts the Kaposi's sarcoma-associated herpesvirus envelope and inhibits infection in oral epithelial cells.

Authors:  David C Brice; Zsolt Toth; Gill Diamond
Journal:  Antiviral Res       Date:  2018-08-02       Impact factor: 5.970

Review 5.  Antiviral Activities of Human Host Defense Peptides.

Authors:  David C Brice; Gill Diamond
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 6.  Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections.

Authors:  Fern Findlay; Lorna Proudfoot; Craig Stevens; Peter G Barlow
Journal:  Pathog Glob Health       Date:  2016-06-17       Impact factor: 2.894

7.  A cross sectional analysis of the role of the antimicrobial peptide cathelicidin in lung function impairment within the ALIVE cohort.

Authors:  Allison A Lambert; Gregory D Kirk; Jacquie Astemborski; Enid R Neptune; Shruti H Mehta; Robert A Wise; M Bradley Drummond
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

Review 8.  Cathelicidin impact on inflammatory cells.

Authors:  Justyna Agier; Magdalena Efenberger; Ewa Brzezińska-Błaszczyk
Journal:  Cent Eur J Immunol       Date:  2015-08-03       Impact factor: 2.085

9.  Cathelicidins display conserved direct antiviral activity towards rhinovirus.

Authors:  Filipa Henderson Sousa; Victor Casanova; Fern Findlay; Craig Stevens; Pavel Svoboda; Jan Pohl; Lorna Proudfoot; Peter G Barlow
Journal:  Peptides       Date:  2017-07-29       Impact factor: 3.750

Review 10.  Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.

Authors:  Stephanie Ascough; Suzanna Paterson; Christopher Chiu
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.